These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22524172)

  • 41. New antithrombotics for atrial fibrillation.
    Bereznicki LR; Peterson GM
    Cardiovasc Ther; 2010 Oct; 28(5):278-86. PubMed ID: 20645985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.
    Bajorek B; Magin PJ; Hilmer S; Krass I
    J Clin Pharm Ther; 2016 Aug; 41(4):432-40. PubMed ID: 27338004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticoagulation therapy for atrial fibrillation.
    Hylek EM
    Semin Thromb Hemost; 2013 Mar; 39(2):147-52. PubMed ID: 23397554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation.
    Indredavik B; Rohweder G; Lydersen S
    J Intern Med; 2005 Aug; 258(2):133-44. PubMed ID: 16018790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidental atrial fibrillation and its management.
    Saliba W
    Postgrad Med; 2011 Mar; 123(2):27-35. PubMed ID: 21474890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Guidelines for stroke prevention in patients with atrial fibrillation.
    Howard PA
    Drugs; 1999 Dec; 58(6):997-1009. PubMed ID: 10651387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
    Altawalbeh SM; Alshogran OY; Smith KJ
    Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of new drugs for management of atrial fibrillation.
    Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
    Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges.
    Khattak F; Alam MB; Paul TK; Rijal S; Wazir S; Lavie CJ; Saba S
    Am J Med Sci; 2018 May; 355(5):467-476. PubMed ID: 29753377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Issues of antithrombotic therapy in ACS patients with atrial fibrillation].
    Kaydalova NA; Koroleva LY; Kovaleva GV; Paykova NN; Nosov VP; Volkova AT; Koryazina AM
    Kardiologiia; 2018 SJan; (S1):22-30. PubMed ID: 29768158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications.
    Goette A
    Trends Cardiovasc Med; 2013 May; 23(4):128-34. PubMed ID: 23313169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atrial fibrillation: stroke prevention in older adults.
    Quinn GR; Fang MC
    Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
    Pujadas-Mestres L; Escolar G; Arellano-Rodrigo E; Galán AM
    Drugs Today (Barc); 2013 Jul; 49(7):425-36. PubMed ID: 23914351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.